Program
AZD8965
A development code. Also written as “AZD8965 low dose”, “AZD8965 medium dose” and “AZD8965 high dose”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 21 open or running | phase 2since May 5, 2026 | Jul 9, 2024 | Sep 18, 2028phase 2 · NCT07652658 |
- Named in AstraZeneca’s own pipeline as
AZD8965
, phase 2, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2024First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT06502379 · 147 enrolled · United States
- May 5, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07652658 · 359 planned · United States, Argentina, Australia and more
Ahead
- Sep 18, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07652658
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07652658Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Recruiting | Sep 18, 2028 | 359 |
| NCT06502379Idiopathic Pulmonary Fibrosis · United States | 1 | Completed | Jun 1, 2025 | 147 |
How it is read
Names in the registry
- “AZD8965 low dose”, 1 entry
- “AZD8965 medium dose”, 1 entry
- “AZD8965 high dose”, 1 entry
- “AZD8965”, 1 entry
Codes read as this program: AZD8965.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.